Abstract
Aim
Patients with advanced renal cell carcinoma and poor performance status (PS≥2) are often deemed unsuitable for treatment. The Pazo2 trial aimed to assess tolerability and efficacy of pazopanib as first-line treatment in renal cancer patients with ECOG PS2.Methods
Pazo2 was a prospective, single arm, open label, multicentre, phase II trial, conducted in 26 UK centres. Eligible patients were aged ≥18 years, with advanced or metastatic renal cancer and a clear cell component (aRCC), measurable disease as per RECIST Criteria 1.1, and ECOG PS2. Co-primary outcomes, assessed at 6-months after patients entered the trial, were tolerability, defined as the proportion of patients who did not develop "intolerable" adverse events, and efficacy, defined as the proportion of all patients who were progression-free and alive.Results
Between February 21, 2013 and August 12, 2016, 75 patients were registered. Median age was 68.6 years (IQR 64.6-76.0), 100% ECOG PS2, 62.7% 'poor risk' (International Metastatic Renal-Cell Carcinoma Database Consortium). Of the 65 evaluable patients, 70.8% (95% CI: 58.8, 80.4) did not develop "intolerable" adverse events and 56.9% (95% CI: 44.8, 68.2) were still alive and progression-free 6 months after starting pazopanib. Twenty-seven patients developed serious adverse events deemed to be related to pazopanib.Conclusion
These data suggests that pazopanib is tolerated and effective in aRCC patients with PS2 and represents a treatment option for patients who cannot receive or tolerate immune checkpoint inhibitors.Full text links
Read article at publisher's site: https://doi.org/10.1016/j.clgc.2022.06.012
Read article for free, from open access legal sources, via Unpaywall: http://www.clinical-genitourinary-cancer.com/article/S1558767322001367/pdf
Citations & impact
This article has not been cited yet.
Impact metrics
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/135966580
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Eur Urol Oncol, 3(5):687-694, 02 Jul 2019
Cited by: 9 articles | PMID: 31272939 | PMCID: PMC6938577
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
J Immunother Cancer, 6(1):109, 22 Oct 2018
Cited by: 91 articles | PMID: 30348216 | PMCID: PMC6196426
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Int J Cancer, 148(4):950-960, 18 Aug 2020
Cited by: 2 articles | PMID: 32738823
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Pharmacoeconomics, 31(1):15-24, 01 Jan 2013
Cited by: 23 articles | PMID: 23329590
Review
Funding
Funders who supported this work.
Cancer Research UK (3)
Grant ID: C22436/A25354
Cancer Research UK Clinical Trials Unit, Birmingham
Professor Pamela Kearns, University of Birmingham
Grant ID: 25354
Grant ID: C11225/A12402